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Abstract
Fibronectin is ubiquitously expressed in the extracellular matrix, and experimental evidence has shown that it
modulates blood vessel formation. The relative contribution of local and circulating fibronectin to blood vessel
formation in vivo remains unknown despite evidence for unexpected roles of circulating fibronectin in various
diseases. Using transgenic mouse models, we established that circulating fibronectin facilitates the growth of
bone metastases by enhancing blood vessel formation and maturation. This effect is more relevant than that of
fibronectin produced by endothelial cells and pericytes, which only exert a small additive effect on vessel maturation.
Circulating fibronectin enhances its local production in tumors through a positive feedback loop and increases the
amount of vascular endothelial growth factor (VEGF) retained in the matrix. Both fibronectin and VEGF then cooperate
to stimulate blood vessel formation. Fibronectin content in the tumor correlates with the number of blood vessels and
tumor growth in the mouse models. Consistent with these results, examination of three separate arrays from patients
with breast and prostate cancers revealed that a high staining intensity for fibronectin in tumors is associated with
increased mortality. These results establish that circulating fibronectin modulates blood vessel formation and tumor
growth by modifying the amount of and the response to VEGF. Furthermore, determination of the fibronectin content
can serve as a prognostic biomarker for breast and prostate cancers and possibly other cancers.
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Introduction
Recent studies have highlighted the key role of the extracellular
matrix in tumor formation by demonstrating that changes in matrix
protein concentrations or matrix composition affect tumor progres-
sion [1,2]. In the light of these results, we have investigated the func-
tion of fibronectin in this context. Fibronectin is a component of the
extracellular matrix and exerts multiple effects in vitro and in vivo
including stimulation of cell proliferation, migration, differentiation,
and survival [3–6]. It affects cell behavior through activation of var-
ious cell surface receptors most notably integrins [7]. Fibronectin is
required for the development of fibrillar structures [8] and for the
storage and activation of various growth factors [9]. Recent studies
of circulating fibronectin have uncovered diverse functions ranging
from promotion of tumor cell invasion to bone matrix integrity
and to improved recovery after brain ischemia. These studies have
raised awareness of the multitude of fibronectin functions [5,10,11].
Breast and prostate cancer cells migrate away from their origin
through the circulation and find a new home in the bone marrow
[12,13] and eventually develop bone metastatic lesions [14]. Clinical
data confirm a correlation between the presence of breast or prostate
cancer cells in the bone marrow and the development of bone metas-
tases [12,13]. There are no studies examining the role of fibronectin
in the bone marrow despite evidence that fibronectin is upregulated
in future sites of lung cancer metastasis [15]. These findings suggest
that fibronectin plays a yet undefined role in the early development
of tumors.
The aim of this study was to examine whether deletion of fibro-
nectin in the bone marrow and in the circulation affects the devel-
opment of breast and prostate cancer cells in the bone marrow niches
and to identify the mechanisms underlying these effects. We found
that circulating fibronectin enhances tumor growth by increasing vas-
cular endothelial growth factor (VEGF) content, VEGF-mediated
signaling, and blood vessel formation.
Materials and Methods
Mice
Mice possessing an Mx or albumin promoter driving cre-recombi-
nase expression were crossed with mice carrying loxP-flanked (floxed)
fibronectin [5] and foxn1 mutation [16]. The presence of homo-
zygote foxn1 mutations results in immune deficiency. Mx was induced
at 3 weeks with three injections of polyinosinic–polycytidylic acid
(pIpC; 250 μg; Amersham, Freiburg, Germany) [5]. Enhanced green
fluorescent protein (eGFP) reporter mice, in which cells expressing cre
produce eGFP and, hence, fluoresce [17], were backcrossed to the
above lines as noted in the text. Growth and homing experiments as
well as most of the experiments reported in conditional knockout
(cKO) animals used littermates as controls. Plasma fibronectin
was determined by ELISA from tail-vein blood [18]. To determine bone
marrow fibronectin, the bone marrow was flushed with 100 μl of pro-
tein lysis buffer/femur, and fibronectin was determined by ELISA cor-
rected to protein content by BCA (Pierce, Bonn, Germany) [10,19,20].
To evaluate the cell types in which fibronectin is deleted due to the pres-
ence of cre, the bone marrow cells were flushed from mice carrying
Mx-cre, which are homozygotes for floxed fibronectin and carry
eGFP. eGFP is produced whenever a stop codon is removed due to
the presence of cre. The cells that were exposed to cre recombinase there-
fore fluoresce green [17]. Cells were then stained with the antibodies
described in the text and below under flow cytometry. For homing
experiments, 105 cancer cells were injected intracardially, and 24 hours
later, DNA was extracted and examined by quantitative polymerase
chain reaction (qPCR) for human alu. Results are adjusted to murine
bone marrow [14,21].
For intracardiac injection of cancer cells, mice were anesthetized
(ketamine/xylazine), and 105 cancer cells per 100 μl of phosphate-
buffered saline were injected into the left ventricle [22]. Tumor growth
was evaluated weekly starting 3 weeks after injection by biolumines-
cence imaging (BLI). Total bioluminescence signal describes the total
tumor burden per mouse [22].
Intratibial injection was performed as described [22]. Briefly, mice
were anesthetized, and two holes were drilled in the left tibia. Bone
marrow was flushed out from the upper hole, which was then sealed.
Cancer cells (5 × 104 per 5 μl of phosphate-buffered saline) were
injected in the lower hole using a Hamilton pipette (75RN;31/2″/3S),
the hole sealed, and the skin sutured. Tumor growth was monitored
starting day 7 and up to 40 days by BLI. Bromodeoxyuridine (BrdU;
100 mg/kg) was injected 1 hour before euthanasia. Tumors obtained
at day 40 were used for histology, protein, and mRNA tests.
BLI was performed using IVIS-100 5 minutes after D-luciferin
(150 mg/kg) (Synchem, Felsberg, Germany) injection. Lytic lesions
were detected by radiography using a Faxitron. Lytic lesions on X-rays
were analyzed using ImageJ (Wayne Rasband, NIH, Bethesda, MD).
For detection of injected fibronectin in tumors, labeled fibronectin
(1 mg) was injected every 12 hours thrice intraperitoneally in mice that
received intratibial cancer cell injections 18 days earlier. Mice were
killed 6 hours after the last injection. Labeling was performed using
Oyster-488 (Dianova, Hamburg, Germany) according to the manufac-
turer’s protocol. Unlabeled fibronectin was removed using Sephadex
columns (GE Healthcare, Freiburg, Germany). Labeled fibronectin
was assessed in a sandwich ELISA confirming maintenance of binding
and expected concentration. Masson-Goldner staining to confirm the
presence of tumor was performed as described [10]. The experiment
was repeated twice with similar results.
Staining Protocols and Immunohistochemistry
Cryosections of 3.7% neutral-buffered formalin-fixed tumors
were stained with the following antibodies: rat anti–mouse CD31
(AbD Serotec, Düsseldorf, Germany), mouse anti–alpha-smooth
muscle actin (α-SMA)-Cy3 (Sigma-Aldrich, Taufkirchen, Germany),
sheep anti-fibronectin, sheep anti-BrdU (Biozol, Eching, Germany),
rabbit anti-desmin, goat anti–sheep-Cy3 (Dianova), rabbit anti–von
Willebrand factor (vWF; Axxora, Lörrach, Germany), rabbit anti–active
caspase-3 (Abcam, Cambridge, United Kingdom), goat anti–rat-Cy2,
or goat anti–rabbit-Alexa-555 (Molecular Probes, Invitrogen, Darmstadt,
Germany). For chromogen staining, EnVision kit (Dako, Hamburg,
Germany) was used. Sections were photographed using a Nikon-90i
microscope and processed using ImageJ. Quantification was performed
in at least three sections per mouse in at least three mice per group or
more as noted in the figure legends. At least 0.9 mm2 was examined per
section.
Cell Isolation and Culture
MDA-MB-231B/luc+ or PC-3M-Pro4/luc+was cultured inDulbecco’s
modified Eagle’s medium (DMEM)/10% fetal calf serum (FCS) with
800 and 500 μg/ml geneticin, respectively [22]. Cells were counted
using an automated cell counter (CASY-TT; Innovatis, Mannheim,
Germany). For some experiments, fibronectin-depleted FCS was
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obtained by running FCS on gelatin-Sepharose columns three to five
times and dialysing against FCS [18]. Successful depletion was con-
firmed by ELISA, and final concentration of fibronectin was 8 to
11 ng/ml.
Isolation of tumor endothelial cells was performed as described
with modifications [23,24]. Briefly, tumors were minced, digested
[1 mg/ml collagenase-A (Serva, Heidelberg, Germany) + 0.05%
DNAse1 (Roche, Mannheim, Germany) at 37°C for 45 minutes
with shaking], filtered, and centrifuged. Pellets were washed and
resuspended inDMEM/10%FCS. Dynabeads (30 μl; Invitrogen) were
precoated with 20 μg of rat anti-CD31 antibody [MEC 7.46] (Abcam).
Cells were added for 1 hour at 4°C, beads were washed, and cells were
released with 0.05% trypsin/EDTA (Gibco, Invitrogen) and cultured
in DMEM/20% FCS, 2 mM L-glutamine, 2 mM sodium pyruvate,
20 mM Hepes, 1% nonessential amino acids, 100 μg/ml streptomycin,
100 UI/ml penicillin, 12 U/ml heparin (fresh), and 100 μg/ml EC
growth supplement (Sigma). Passages 3 to 5 were used. To determine
fibronectin production, cells were cultured for 72 hours in the presence
of 20% fibronectin-depleted FCS.
Pericytes were isolated from the bone marrow using Dynabeads
(Invitrogen) coated withCD45 (clone 30-F11; BioLegend, Fell, Germany)
followed by Dynabeads coated with rat anti–mouse-angiopoietin-1
(Abcam). Angiopoietin-1–coated beads were treated with RNA lysis
buffer or cultured for 24 hours in the presence of 10% fibronectin-
depleted FCS. Pericytes stained for angiopoietin-1 were also sorted
using FACSVantage and cultured or examined by flow cytometry
for α-SMA staining.
Proliferation was performed as follows: 27,000 cells per 200 μl of
DMEM either without FCS (cancer) or with 20% fibronectin-
depleted FCS (endothelial cells) were seeded, cultured for 36 (cancer)
or 48 hours (endothelial cells), and counted as above. For endothelial
cells, fibronectin was added at 200 μg/ml and recombinant human
VEGF-165 (Spodoptera frigiperda; R&D Systems, Abingdon, United
Kingdom) at 6 ng/ml. Signaling molecules were examined in cells
seeded overnight and activated with fibronectin, VEGF, or both
without FCS for 15 minutes, and the reaction was stopped on ice
followed by washing twice. BCA was used to quantify protein content
(Pierce), and 100 μg was loaded onto each lane in 10% gels.
Fibronectin assembly was inhibited by daily adding 500 nM FUD
[25] and compared to scrambled peptide, 200 μg/ml fibronectin, or
no addition. In another experiment, cells were treated either with
200 μg/ml fibronectin, 6 ng/ml VEGF, both fibronectin and VEGF,
or left untreated. Substances were added directly after plating 106 cells
in 2 ml/well of a six-well-plate (total FN, 400 μg and total VEGF,
12 ng). In both experiments, cells were left in culture for 72 hours, then
treated with 1% deoxycholate as described [8]. The insoluble fraction
(DOC insoluble) represents matrix. Fibronectin and human VEGF
ELISA results were corrected to total protein.
Flow Cytometry
Bone marrow was flushed from femora as described above, and cells
stained with the following antibodies: rat anti–plasma-lemma-vesicle-
associated protein–AF-647 (MECA-32; AbDSerotec), rat anti–CD31-PE
(clone MEC13.3; BioLegend), rabbit anti-desmin, mouse anti–α-SMA-
Cy3 (Sigma-Aldrich), rat anti–mouse-angiopoietin-1 (Abcam), goat
anti–rabbit-Cy3 (Dianova), and rat anti–CD45-Pacific Blue or APC-
Cy7 (clone 30-F11; BioLegend). Flow cytometry was performed using
LSR-2 (BD Biosciences, Heidelberg, Germany). Examination of eGFP
expression in pericytes was performed on stroma obtained from the
bone marrow after depletion using CD45-coated Dynabeads.
For Annexin V/propidium iodide (AV/PI) staining, tumors were
minced and digested, and 106 cells were resuspended in 50 μl of AV/PI
binding buffer [10 mMHepes (pH 7.4), 140 mMNaCl, and 2.5 mM
CaCl2]. AV (12.5 μg/μl) and PI (1 μg/ml) were added (BioLegend) for
30 minutes at room temperature in the dark, and samples were mea-
sured within 20 minutes.
DNA Analysis
Genomic DNA was isolated from femora using DNeasy Blood
and Tissue Kit (Qiagen, Hilden, Germany). Real-time qPCR was
performed using LightCycler 2.0 (Roche) using the primers and
probes for alu as described [21]. Results were normalized to murine
β-actin. An external standard curve using known numbers of human
and mouse cells was created for both alu and β-actin. We were able to
detect 0.2 cancer cell/106 mouse cells.
RNA Analysis
RNA was isolated using RNeasy (Qiagen) and reversed transcribed
using iScript-Select (Bio-Rad, Munich, Germany). qPCR results
were normalized to murine β-actin or human HPRT. The probes
used were given as follows: murine fibronectin #66; human fibronec-
tin #76; human HPRT #22; murine β-actin #64; RGS5 #31 [26];
VEGF-A, both human and murine #64 with different primers; murine
VEGF receptor 2 (VEGFR-2) #62. The primers used were those sug-
gested by Roche universal probe library except for human fibronectin:
5′actgagactccgagtcagcc, 3′ttccaacggcctacagaatt.
Protein Analysis
For Western blot analysis, the following antibodies were used:
anti–fibronectin-HRP (Dako), β-tubulin (Sigma-Aldrich), Bcl-2,
BAX (BD Pharmingen, Heidelberg, Germany), extracellular signal-
regulated kinase (ERK), pERK, AKT, pAKT, stress-activated protein
kinase/Jun amino-terminal kinase (SAPK/JNK) kinase, pSAPK/JNK
kinase, VEGFR-2, pVEGFR-2 (Cell Signaling Technology, Frankfurt,
Germany), focal adhesion kinase (FAK; Millipore, Schwalbach,
Germany), and pFAK (Biosource, Invitrogen). All antibodies were
diluted 1:1000. Samples were loaded after adjusting to protein content
measured by BCA (Pierce).
Fibronectin was quantified in mouse plasma, cell lysates, and con-
ditioned media by ELISA as reported [18,19] and corrected to pro-
tein content measured by BCA (Pierce) when appropriate. Briefly,
plates were coated with the primary antibody (0.12 μg/ml, F3648;
Sigma). For mouse plasma, bone marrow lysates, conditioned media
of endothelial cells, and tumor samples, the standard used was murine
plasma fibronectin (#IMFBN; Dunn, Asbach, Germany). For tumor
lysates, the standard used was human plasma fibronectin isolated as
described [10]. The secondary anti–fibronectin-HRP antibody
(P0246; Dako) was used.
VEGF was quantified in tumor tissue samples lysed in protein lysis
buffer and applied in mouse and human VEGF ELISAs (dilution of
1:5 and 1:8, respectively) as well as in cell culture material (dilution
of 1:5 and 1:2 for medium and DOC soluble and insoluble fractions
according to the manufacturer’s recommendations, respectively;
R&D Systems).
Neoplasia Vol. 15, No. 8, 2013 Circulating Fibronectin Controls Tumor Growth von Au et al. 927
Patients
Tumor tissue samples from three tissue microarrays were stained.
Samples were evaluated for intensity of staining and scored on a scale
of 0 to 2 by a person blinded to the follow-up data. The breast cancer
tissue microarray included 100 primary tumor samples of untreated
patients diagnosed and operated upon in the years 2003 to 2007 with
a follow-up until January 2012 (median follow-up of 88 months).
Patient survival data of the first untreated prostate cancer array were
available for at least 5 years after diagnosis. The second prostate
array included primary tumors of 116 untreated patients operated
in 2002 to 2004 with follow-up until 2011 (median follow-up of
73 months).
Statistical Analyses
Analyses were performed using SPSS (V20). Analysis of variance
and repeated measures analysis of variance tests were used as appro-
priate. If global probability values were smaller than 5%, subsequent
comparisons between selected group pairs were then performed using
Student’s t, Mann-Whitney, or Wilcoxon paired tests as appropriate.
Pearson correlations were estimated to evaluate the relationship be-
tween two variables. The 5-year survival rates from patients in the
first prostate array were explored using a Jonckheere-Terpstra exact
test (SAS), which takes into account the ordering of staining inten-
sities. The other two patient collectives were investigated by relying
on Kaplan-Meier survival curves and Cox regression. Results are
expressed as means ± SEM.
Results
Deletion of Fibronectin Using the Albumin or
Mx Promoter Attached to Cre
Our aim was to examine the role of fibronectin in the formation of
bone metastases. We used an MDA-MB-231B/luc+ human cancer
cell line that has been selected for its ability to home to the bone
marrow and reliably establish bone metastases [22]. This cancer line
needs to be applied into mice that are immune deficient. We there-
fore used mice homozygote for the foxn1nu mutation making them
nude and resulting in absence of functional T-cells and inability to
reject the human cancer cells [16].
Since fibronectin knockout mice die in utero, we used two cKO
models in the immune-deficient mice: The albumin promoter at-
tached to cre recombinase is spontaneously active and results in a
gradual deletion of fibronectin in the hepatocytes and, hence, a slow
loss of circulating fibronectin that is completed by 8 weeks of age in
mice that are homozygote for the floxed fibronectin gene (Alb-cKO).
The second promoter, the Mx promoter, attached to cre recombinase
[5] can be activated in 3-week-old homozygote fibronectin-floxed
mice by injecting polyinosinic–polycytidylic acid. This results in
deletion of circulating fibronectin already by 4 weeks of age, because
the Mx promoter is also active in hepatocytes (Figure 1A). Unlike the
Alb-cKOmodel that is specific for circulating fibronectin, the Mx-cKO
model results in deletion of fibronectin in the bone marrow (Figures 1B
andW1A). To determine which cell types in the bone marrow undergo
deletion in the Mx model, we used eGFP reporter mice that were
homozygotes for the fibronectin-floxed gene [17]. Cells in which cre
recombinase is activated should both express eGFP and show deletion
of fibronectin, and hence, the number of eGFP-expressing cells will
be higher in Mx-cKO mice. In Mx-cKO, eGFP was expressed in
CD45+ cells, endothelial cells [27], sinusoidal cells [28], and peri-
cytes (Figure 1C ) [29,30]. Using both cKO models, we should be
able to define the role of circulating fibronectin and find out whether
bone marrow fibronectin affects cancer development.
Deletion of Fibronectin in the Circulation
Affected Tumor Growth
We sought to examine the role of fibronectin in homing of cancer
cells to the bone marrow and early growth of bone metastases. The
above-mentioned MDA-MB-231 cell line expresses luciferase (luc+),
and therefore, BLI could be used to monitor tumor development
longitudinally (Figure W1B) [22].
Intracardiac injection of cancer cells is performed in 4-week-old
mice, when bone lesions reliably form in all mice. At 4 weeks, fibro-
nectin in the circulation was decreased by 95% in Mx-cKO and 40%
in Alb-cKO mice (Figure 1A) for the reasons discussed above. Fibro-
nectin in the bone marrow is only affected in Mx-cKO, however
(Figures 1B and W1A). Thus, if bone marrow fibronectin does not
affect tumor growth, the intracardiac model allows for a comparison
between the effect of a small and a large decrease in circulating fibro-
nectin levels. Intracardiac cancer cell injection in Mx-cKO and Alb-
cKO mice did not affect the number of tumor lesions compared to
littermate controls (CT; Figure W1C ) nor the number of cancer cells
that homed to bone marrow [21] (Figure W1D). There were two
differences nevertheless. Only in Mx-cKO was tumor burden per
mouse decreased (Figure 1D), and median survival was increased
from 6.6 weeks in CT to 8.6 weeks in Mx-cKO (P < .05;
Figure 1E ). These data suggest that prolongation of survival and de-
creased tumor burden in Mx-cKO mice is not due to decreased hom-
ing to the bone marrow but to decreased growth. Furthermore, the
normal growth in Alb-cKO suggests that either a decrease in circu-
lating fibronectin by 40% does not affect tumor growth or that bone
marrow fibronectin is critical for tumor growth.
To differentiate between these two possibilities, a role of circulating
fibronectin or bone marrow fibronectin, we looked for a model that
can be used in 8-week-old mice when both Alb-cKO and Mx-cKO
mice show similar deletion in circulating fibronectin (Figure 1A). Intra-
tibial injection of cancer cells is usually performed at this age [22].
Induction of a single bone lesion in the tibia offers an additional advan-
tage of providing comparable tissue samples for further studies [22].
Using this model, tumor growth in Mx-cKO and Alb-cKO mice was
similarly decreased by 50% (Figure 1F). This was confirmed by a de-
crease in cancer-induced osteolysis at the site of tumor growth
(Figure W1E). Since at the age of 8 weeks Alb-cKO andMx-cKO only
differ in the absence of fibronectin in the bone marrow of Mx-cKO,
these data suggest that circulating fibronectin and not bone marrow
fibronectin affected tumor growth.
To determine whether the effects of circulating fibronectin can be
reproduced in other cancer types, we used the prostate cancer cell
line PC3Mpro4/luc+. Intratibial injection in CT, Mx-cKO, and
Alb-cKO mice showed similar effects to those described (Figure W2).
Thus, the conclusion that circulating fibronectin affects tumor growth
is not limited to MDA-MB-231.
Circulating Fibronectin Infiltrates Tumor Tissue and
Modulates Its Own Production in Tumor
Since circulating fibronectin affected tumor growth, we asked
whether this effect might be due to infiltration of circulating fibro-
nectin into tumor tissue. Two results supported this conclusion.
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First, injected prelabeled plasma fibronectin could be detected in
tumor tissue (Figure 2A), and second, the decrease in circulating
fibronectin found in Mx-cKO and Alb-cKO was associated with a
decrease in fibronectin content in both Mx- and Alb-cKO tumors
compared to CT as determined by staining intensity and protein
amounts measured by ELISA (Figure 2, B and C ). The amount of
fibronectin measured by ELISA in tumor tissue in Mx- and Alb-cKO
was about 1/10th that in CT (Figure 2C ).
It has been suggested that fibronectin increases its own production
[31]. We therefore examined whether the decrease in circulating
fibronectin and, hence, fibronectin infiltration affected the amount
of fibronectin produced locally in tumor tissue. To do, this we de-
signed human- and mouse-specific primers for fibronectin. Species
specificity in qPCR was confirmed. Both local cancer cell (human)
and stromal (murine) fibronectin production were diminished in
Alb-cKO and Mx-cKO (Figure 2D). This suggests that circulating
fibronectin infiltrating the tissue enhances the amount of local fibro-
nectin produced. Thus, both diminished circulating fibronectin and
suppressed local fibronectin production contribute to a decrease in
fibronectin content in tumors.
Establishing the Reasons for Decreased Growth in the cKO Mice
Fibronectin has been implicated in blood vessel formation [32].
Furthermore, it directly stimulates proliferation and inhibits apopto-
sis [33]. Thus, the decrease in fibronectin content could, through
these mechanisms, result in decreased tumor growth. We therefore
evaluated these three possibilities.
Angiogenesis in vivo. We first evaluated the effect of circulating
fibronectin on blood vessel formation. Because we had expected a
more pronounced effect on growth in Mx-cKO mice, we first deter-
mined whether Mx was indeed able to delete fibronectin in vascular
cells. We therefore isolated tumor endothelial cells and marrow peri-
cytes fromMx-cKOmice using CD31 and angiopoietin-1 antibodies,
respectively. Isolated endothelial cells stained with vWF (98%) and
pericytes with α-SMA (97%; Figure W3, A and B). Successful fibro-
nectin deletion was confirmed in both cell types originating from
Mx-cKO mice compared to CT by measuring fibronectin protein
in conditioned media using ELISA (Figure 3, A and B). Evaluation
of the vascular supply by staining for CD31 in tumor sections re-
vealed diminished vascularization per unit area in tumors from both
Figure 1. Deletion of fibronectin in Mx-cKO and Alb-cKO mice affects tumor development. (A) Circulating fibronectin in Alb-cKO mice is
decreased by 40% at 4 weeks and 87% at 8 weeks of age, while levels in Mx-cKO were decreased by 87% and 95% compared to
controls (CT) as determined by ELISA (N = 9-11/time point per group). (B) Deletion of fibronectin in the bone marrow in Mx-cKO is
successful and stable for at least 2 weeks after the last pIpC injection, while deletion of circulating fibronectin did not affect fibronectin
amount in the bone marrow of Alb-cKO mice. Bone marrow was flushed with 100 μl of protein lysis buffer/femur. Fibronectin was
measured by ELISA and corrected to protein content measured by BCA (N = 3/group). (C) Use of the Mx promoter leads to deletion
of fibronectin in leukocytes (CD45+), endothelial cells (CD31+), sinusoidal cells (CD31+/PLVAP+), and pericytes (desmin+). Bone
marrow was flushed from mice that express eGFP in cells in which the Mx promoter was activated and, hence, are green, stained,
and examined by flow cytometry. (D) The total bioluminescence signal (tumor burden/mouse) was similar between CT and Alb-cKO
but was smaller in Mx-cKO after intracardiac injection (N = 11-12/group). (E) Median survival was increased by 2 weeks in Mx-cKO.
(F) Intratibial injection is associated with a decrease in bioluminescence signal in both Alb- and Mx-cKO starting at day 14 post-injection
until the end of the experiment at day 40 (N = 9-11/group). The values on the y-axis represent mean bioluminescence signal of the bars
shown. *P < .05, **P < .01, ***P < .0001.
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cKOs using both breast and prostate cancer cell lines (Figures 3, C
andD, and W4). There was no difference however between Mx- and
Alb-cKO tumors in vessel density despite the successful deletion of
fibronectin in endothelial cells and pericytes in Mx-cKO mice.
Thus, the decrease in blood vessel numbers was not affected by fibro-
nectin production in vascular cells.
Because pericyte recruitment and, hence, blood vessel maturation
are affected by extracellular matrix proteins including fibronectin
[30,34], tumor sections were stained with both α-SMA to detect
pericytes and CD31 to detect endothelial cells. The percentage of
blood vessels (identified by CD31 staining) that, at the same time,
showed α-SMA–stained cells was smaller in cKOs, suggesting that
Figure 2. The role of circulating fibronectin. (A) Labeled fibronectin can be detected within the tumor after injection. Masson-Goldner
stain confirms the presence of cancer. Bars represent 500 μm. (B) Fibronectin staining was diminished in Alb- and Mx-cKO tumors. Bars
represent 100 μm. (C) Quantifying the area of staining showed a decrease by more than 60% in Alb- and Mx-cKO tumors compared to
controls (N = 3-4 mice/group). Similarly, quantifying the amount of fibronectin in tumors by ELISA reveals that CT tumors had more than
10-fold higher fibronectin content compared to Alb-cKO and Mx-cKO tumors. Fibronectin was examined by ELISA and values adjusted to
protein (N = 3-6/group). (D) Both cancer cell fibronectin mRNA expression corrected to human HPRT and stromal fibronectin mRNA
expression corrected to murine α-actin are decreased in Alb- and Mx-cKO (N = 4/group). *P < .05, **P < .001.
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the absence of fibronectin leads to decreased vessel maturation
(Figures 3E and W5, A–C ). These findings were confirmed by
staining with desmin, another pericyte marker together with CD31
(Figure W5, D and E ). Nevertheless, the percentage of vessels
covered with pericytes was higher in Alb- compared to Mx-cKO
(Figures 3E and W5E ). Lastly, mRNA for the pericyte marker
RGS5 in tumor tissue [26] was also diminished in cKO tumors
(Figure W5F).
On the basis of these findings, we conclude that circulating fibro-
nectin plays a key role in tumor growth by supporting blood vessel
formation. Blood vessel maturation, however, is controlled by both
vascular fibronectin and circulating fibronectin.
Figure 3. Effects of fibronectin on angiogenesis. (A) Conditioned media from endothelial cells originating from Mx-cKO tumors do not
produce fibronectin compared to endothelial cells originating from Alb-cKO or CT tumors (N = 3-5 replicates/group). (B) Fibronectin
production in conditioned media is decreased in pericytes from Mx-cKO mice. Isolated cells were cultured for 24 hours. (C) Sections
from CT, Alb-, and Mx-cKO intratibial tumors show a difference in the number of CD31-stained blood vessels. Bars represent 100 μm.
(D) The number of CD31-stained blood vessels as well as the area covered by these vessels was decreased in Alb- and Mx-cKO tumors
at 40 days post-injection (N = 6 tumors/group, six sections/tumor). (E) The percentage of blood vessels co-stained for CD31 and α-SMA
was evaluated. The decrease in the percentage of α-SMA+ blood vessels was more pronounced in Mx- than in Alb-cKO tumors. For the
purpose of this graph, the number of CT, Alb-cKO, and Mx-cKO CD31+ vessels was set at 100% (N = 3, 3, 6 mice, four sections/
mouse). *P < .05, **P < .01, ***P < .0001.
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Effects on VEGF and VEGF-mediated signaling. Fibronectin
has multiple binding sites for VEGF [35] and fibronectin matrix
functions as a reservoir for VEGF [9]. We therefore examined whether
VEGF is affected in tumor samples. To differentiate between VEGF
originating from cancer and stromal cells, two species-specific ELISA
kits against human (hence cancer cell) and murine (hence, stromal cells)
VEGF were used. Testing of tumor tissue ex vivo revealed a significant
decrease in cancer cell VEGF protein corrected to total protein but not
stromal VEGF as measured in the respective ELISAs (Figures 4A and
W6A). The decrease in cancer cell VEGF protein was not associated
with a change in cancer cell VEGF mRNA expression (Figure W6B),
suggesting that storage ofVEGFwas diminished in cKO tumors. To test
this in vitro, cancer cells were cultured in the presence of fibronectin-
depleted FCS without additives, in the presence of a peptide that
prevents fibronectin deposition (called FUD) [25], a scrambled pep-
tide, or added fibronectin to the medium (200 μg/ml). Matrix fibro-
nectin was decreased in the presence of FUD and increased in the
presence of added fibronectin. Concordant changes in matrix VEGF
could be detected (Figure 4B, right axis). Furthermore, the addition of
fibronectin to the medium resulted in an increase in the matrix of re-
trieved endogenous VEGF (Figure 4C , left two bars) as well as exoge-
nously added VEGF (third and fourth bars). VEGF in media or cell
lysates did not differ however (data not shown). These data suggest
that indeed the presence of fibronectin in the matrix contributes to
retention of VEGF in the matrix and that in cKO tumors the decrease
in fibronectin content contributes to loss of VEGF from the matrix.
We next asked whether the decrease in VEGF affected signaling.
Because the proangiogenic effects of VEGF are mainly mediated
through VEGFR-2, we first established murine- and human-specific
qPCR primers for VEGFR-2. Murine VEGFR-2 mRNA expression
was diminished in tumor samples from cKO mice, while human
VEGFR-2 was not changed (Figures 4D and W6C ), suggesting that
the decrease in VEGF in tumors was associated with a decrease in the
expression of its receptor on murine stromal cells. Furthermore, the
amount of phosphorylated VEGFR-2 was diminished in cKO
tumors, suggesting that signaling through this receptor was also dimin-
ished (Figure 4E ).
These data support the conclusion that the amount of stored
VEGF as well as VEGF-mediated signaling is diminished in vivo in
Mx- and Alb-cKO tumors. Thus, the amount of fibronectin in tumors
seems to control signaling by VEGF.
Fibronectin cooperates with growth factors to induce intracellular
signals [36]. We therefore asked whether the decrease in stored
VEGF solely was responsible for decreased blood vessel formation
or whether the decrease in fibronectin contributed to the decrease
in VEGF-mediated signaling in our model. To begin to address this
issue, we used proliferation as a proxy measure for collaboration of
both fibronectin and VEGF. Proliferation of tumor endothelial cells
in vitro was significantly increased by either adding fibronectin or
VEGF to endothelial cells isolated from CT tumors (Figure 4F ). Pro-
liferation of Mx-cKO cells was increased by the addition of fibro-
nectin but was not changed by VEGF alone, presumably because
of the absence of endogenous fibronectin shown above (Fig-
ure W6D). The combination of fibronectin and VEGF resulted in
the best response in endothelial cells, however. Thus, fibronectin
and VEGF seem to exert synergistic effects on proliferation. In sup-
port of these findings, both phospho-ERK and phospho-AKT in-
creased in the presence of both fibronectin and VEGF and, in the
case of phospho-AKT, more so than when either one was added
alone, while neither phospho-FAK nor phospho-JNK showed signif-
icant changes (Figures 4, G–I , and W6, E and F ). This is in line
with an additive effect of fibronectin and VEGF on cells.
Thus, circulating fibronectin infiltrates tumor tissue, increases local
fibronectin production and VEGF retention, and together with
VEGF potentiates intracellular signals and, hence, increases blood
vessel formation. It thus seems that in this context fibronectin is more
relevant for tumor growth than VEGF.
Effects on proliferation and apoptosis. Fibronectin can directly
affect proliferation [33]. We therefore evaluated BrdU incorporation
in tumors in vivo by staining and found that proliferation was indeed
diminished in cKO (Figure 5, A and B). We confirmed a direct effect
of fibronectin on proliferation by showing a dose response in cancer
cells in vitro to fibronectin, whereby proliferation in response to
500 μg/ml fibronectin was equivalent to 10% fibronectin-depleted
FCS (Figure 5C ) establishing a proliferative role for fibronectin on
our tumor cells that is equivalent to the growth factors found in FCS.
Apoptosis in tumors was increased in cKO mice as measured
by terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining in sections (Figure 5, D and E ). This was con-
firmed in cell suspensions from tumors treated with collagenase and
stained with AV and PI (Figure W7, A and B). This increase was
not mediated by an effect on cleaved caspase-3 evidenced by lack of a
difference in staining between CT and cKOs (Figure W7, C andD). It
has been reported that an increase in BAX can mediate mitochondrial
damage and cell death without caspase-3 involvement [37]. In line
with this but unlike published reports on the effects of fibronectin in
apoptosis [38], the expression of the antiapoptotic protein Bcl-2 was
the same, but the proapoptotic protein BAX was higher in cKO
(Figure 5F ). This suggests that the increase in cell death is mediated
by an increase in BAX.
Taken together, these data suggest that diminished fibronectin in
tumor results in suppressed tumor growth due to decreased angio-
genesis and proliferation and increased apoptosis.
Relevance for Human Cancer
Since fibronectin amount affects VEGF content, blood vessel
formation, and growth, we asked whether in our murine model
increased tumor fibronectin correlates with cancer growth. This
was the case, whereby increased tumor fibronectin resulted in an
increase in blood vessel formation and increased tumor burden (Fig-
ures 6, A and B, and W8).
To determine whether such an association could be reproduced in
breast cancer patients, we examined an array of breast cancer biopsies
of patients with a median follow-up of 88 months. Eighty-one samples
could be evaluated for fibronectin staining. Fifty-four biopsies showed
no staining, 18 weak staining, and 9 strong staining (Figure 6C and
Table 1). Kaplan-Meier survival curves were not different between
patients with tumors either without or with weak staining. Patients
with tumors with strong staining intensity showed poorer survival
(Figure 6E). Only fibronectin staining intensity and estrogen receptor
status (ER) associated with cancer-specific survival (Table 1), whereby
8 of 9 tumors (89%) with strong staining intensity were ER negative
compared to 34 of 72 tumors with no or weak fibronectin staining
(47%; Figure 6D), and in the group in which ER was negative, strong
fibronectin staining intensity correlated with decreased survival (P <
.05). There was no correlation between fibronectin staining intensity
and tumor size (T), nodal state (N), progesterone receptor (PR) status,
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Figure 4. Mechanistic insights on the reason for decreased angiogenesis. (A) Cancer cell VEGF (by human-specific ELISA) was signif-
icantly diminished in tumors originating from cKO mice (N = 4-6/group). (B) A change in matrix fibronectin is associated with a con-
cordant change in VEGF content in the matrix. Cancer cells were cultured in the presence of a peptide (FUD) that inhibits fibronectin
deposition or in the presence of 200 μg/ml fibronectin (FN). Matrix was isolated on the basis of deoxycholate (DOC) insolubility, tested
for fibronectin and VEGF by ELISA, and adjusted to total protein (N = 4-6/group). (C) Fibronectin retains both endogenous (CT vs FN) and
exogenous VEGF (VEGF vs FN/VEGF) in the matrix. MDA cells were cultured for 72 hours in six-well plates without additives, in the
presence of 400 μg of fibronectin, 12 ng of VEGF, or both. Matrix VEGF was quantified and corrected to protein in the DOC insoluble
fraction as in B (N = 3-4/group). (D) Murine VEGFR-2 mRNA expression was diminished in cKO tumors, but human (Figure W6C ) was
not (N = 4/group). (E) The amount of phosphorylated VEGFR-2 was also diminished in cKO tumors in densitometry measurements. An
example of a Western blot is shown on the right (N = 4/group). (F) Cell proliferation was significantly increased when endothelial cells
were treated with either fibronectin or VEGF compared to untreated cells. The addition of both simultaneously resulted in a more pro-
nounced increase in proliferation (N = 3 experiments with three to five replicates/condition per experiment). (G) Both phospho-ERK and
phospho-AKT increased 15 minutes after the addition of both fibronectin and VEGF, while phospho-FAK and phospho-JNK did not. (H and I)
Densitometries of phospho-AKT and phospho-ERK corrected to total AKT and ERK, respectively. *P < .05, **P < .01, ***P < .0001.
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Figure 5. Effects of fibronectin content on proliferation and apoptosis. (A) The number of proliferating cells stained for BrdU in cKO
tumors is diminished. Bars represent 100 μm. (B) Quantitative analysis of BrdU+ cells in tumors (N = 6 CT, 5 Alb-, and 5 Mx-cKO
tumors). (C) Proliferation of tumor cells is improved by the addition of fibronectin. Fibronectin (500 μg/ml) and 10% fibronectin-depleted
FCS increase proliferation to a similar extent. (D) TUNEL staining in tumor tissue from CT, Alb-, and Mx-cKOmice. Bars represent 200 μm.
(E) The number of TUNEL-stained cells is increased in cKO tumors (N = 3-4/group). (F) Western blot analysis for Bcl-2 and BAX shows
an increase in BAX in the absence of circulating fibronectin. A graph of densitometry of values adjusted to β-tubulin is shown on the left.
On the right, an example is presented (N = 3/group).
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or HER2 status. In a Cox regression model including fibronectin
staining, T, N, ER, PR, and HER2 status, the model was significant
(P < .05). A stepwise forward variable selection, however, identified ER
status as the only significant predictive factor, while fibronectin barely
failed significance at P = .06.
To determine whether other tumors showed a similar relationship,
we investigated the relationship between fibronectin staining inten-
sity in tumor and the 5-year risk of death in a cohort of 82 patients
with localized prostate cancer. None of the patients without staining
on a scale of 0 to 2 died (0/48), while 1 of 28 (4% of patients) with
weak staining and 2 of 6 (33% of patients) with strong staining died
(0.006). No relationship between fibronectin staining intensity and
Gleason score, tumor stage, lymph node metastasis, or relapse was
found, however.
On the basis of these encouraging results, we expanded the anal-
ysis to a second prostate array of patients who underwent radical
Figure 6. Implications and relevance in human cancer. (A) Fibronectin content in tumors correlates with blood vessel numbers in the
whole group including CT, Alb-cKO, and Mx-cKO mice (N = 4 CT, 3 Alb-cKO, and 3 Mx-cKO). Fibronectin content was determined by
ELISA and corrected to protein content. (B) Fibronectin content in tumors determined by ELISA correlates with bioluminescence signal
in the same groups as A. (C) Grading of staining intensity for breast and prostate cancer tissue arrays. (D) Fibronectin staining intensity is
stronger in tumors that are ER negative (ER− = 42, ER+ = 39 samples). Kaplan-Meier survival curves for different fibronectin staining
intensities in (E) breast cancer (N = 81) and (F) prostate cancer (N = 89). *P < .05, **P < .01, ***P < .001.
Table 1. Clinical and Histopathologic Characteristics of the Patients in the Breast Cancer Tissue Microarray.
Effect Level Number of Patients Cancer-Specific Survival Time to Local Recurrence Time to Metastasis Formation
Global P Events HR with 95% CI Global P Events HR with 95% CI Global P Events HR with 95% CI
Age at diagnosis ≤50 20 .182 8 (Ref.) .973 2 (Ref.) .259 9 (Ref.)
>50 61 15 0.56 (0.24-1.33) 6 0.97 (0.20-4.83) 21 1.56 (0.71-3.42)
T 1 40 .118 7 (Ref.) .361 2 (Ref.) .001 8 (Ref.)
2 31 12 2.65 (1.04-6.74) 5 3.70 (0.72-19.16) 15 3.36 (1.42-7.97)
3 8 4 1.99 (0.67-5.91 1 1.39 (0.17-11.64) 6 2.70 (1.08-6.72)
4 2 0 – 0 – 1 1.58 (0.21-11.69)
N 0 46 .266 9 (Ref.) .496 4 (Ref.) <.001 11 (Ref.)
1 18 9 2.85 (1.13-7.19) 4 3.02 (0.75-12.07) 7 1.88 (0.73-4.86)
2 6 1 0.50 (0.67-3.75) 0 – 4 2.78 (0.93-8.25)
3 10 4 1.77 (0.52-6.00) 0 – 7 2.11 (0.88-5.06)
4 1 0 – 0 – 1 61.50 (3.84-985)
ER Negative 42 <.001 19 (Ref.) .027 7 (Ref.) .033 19 (Ref.)
Positive 39 4 0.18 (0.06-0.53) 1 0.13 (0.02-1.09) 11 0.45 (0.22-0.96)
PR Negative 51 .396 16 (Ref.) .436 6 (Ref.) .133 22 (Ref.)
Positive 30 7 0.68 (0.28-1.66) 2 0.56 (0.11-2.65) 8 0.54 (0.24-1.22)
HER2 Negative 63 .585 17 (Ref.) .833 6 (Ref.) .276 26 (Ref.)
Positive 18 6 1.30 (0.51-3.29) 2 1.19 (0.24-5.89) 4 0.56 (0.20-1.61)
Fibronectin score 0 54 .013 13 (Ref.) .6699 5 (Ref.) .124 19 (Ref.)
1 18 5 0.96 (0.31-2.93) 2 1.20 (0.23-6.20) 7 1.31 (0.55-3.11)
2 9 5 4.61 (1.73-12.31) 1 1.43 (0.17-12.10) 4 1.71 (0.58-5.04)
Fibronectin score 0 + 1 72 <.001 17 (Ref.) .706 7 (Ref.) .259 26 (Ref.)
2 9 6 4.56 (1.79-11.63) 1 1.50 (0.18-12.27) 4 1.83 (0.63-2.30)
T indicates tumor size; N, nodal status; HR, hazard ratio; CI, confidence interval; Ref., reference. Significant P values are bolded.
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prostatectomy with a median follow-up of 73 months. Eighty-nine
biopsies could be evaluated for fibronectin staining. Forty-one samples
showed no staining, 36 weak staining, and 12 strong staining
(Figure 6C and Table 2). The presence of positive regional lymph
nodes was higher in tumors with strong staining (0% without staining
vs 20% with strong staining, P < .01). There was no relationship
however between staining intensity and either prostate-specific antigen
concentration, Gleason score, or tumor expansion (T) at diagnosis.
Kaplan-Meier survival curves showed no difference between survival
of patients with tumors either without or with weak staining, but
cancer-specific survival of the relatively small group of patients with
tumors with strong staining was diminished (Figure 6F ). Indeed, a
Cox regression model analysis that included T, N, Gleason score,
and fibronectin staining intensity (none or weak vs strong) identified
fibronectin staining as the only significant predictive factor (P < .05).
The same was true of metastasis-free survival, while none of the exam-
ined parameters correlated with time to biochemical recurrence.
In summary, strong fibronectin staining intensity albeit a relatively
rare event is associated with poor cancer-specific survival (Figure 6,
E and F ).
Discussion
The principal findings of our study are given as follows: 1) Deletion
of circulating fibronectin results in decreased tumor growth. This is
mediated by decreased fibronectin content resulting in lower VEGF
concentrations, suppressed angiogenesis, as well as diminished prolif-
eration and enhanced apoptosis. 2) The amount of tumor fibronectin
seems to be prognostically relevant in human breast and prostate
cancers. Thus, circulating fibronectin by affecting local fibronectin
production contributes to tumor progression and prognosis.
Deletion of fibronectin in the circulation and in the bone marrow
did not affect cancer cell homing to the bone marrow or the number
of metastatic lesions in our model. This is in contrast to findings by
Malik et al. in a lung cancer model [11], where deletion of fibronectin
resulted in a decrease in the number of lung lesions. This was attrib-
uted to fibronectin-containing clots that protect cancer cells in the
circulation and facilitate extravasation. The difference between both
models could be the presence of sinusoids in the bone marrow but not
in the lungs. These sinusoids allow for easy extravasation similar to the
case with liver metastases [11,39]. Furthermore, our findings suggest
that in the absence of circulating fibronectin bone marrow fibro-
nectin content does not enhance the establishment potential of circu-
lating cancer cells in the bone marrow, despite published reports that
local fibronectin provides a permissive environment for lung cancer
metastasis [15].
Tumor growth depends on the formation of blood vessels. During
the early steps of angiogenesis, endothelial cells modify the surround-
ing extracellular matrix and produce fibronectin [25,40]. Endothelial
cells from Mx-cKO showed reduced proliferation that partially nor-
malized by addition of exogenous fibronectin. This is consistent with
in vitro work showing that soluble fibronectin is integrated in the
matrix in a cell-dependent manner [41] and confirmed by our results
showing incorporation of injected labeled fibronectin in tumor tissue.
Our findings further suggest that endothelial fibronectin can be mostly
replaced by circulating fibronectin.
A key step in angiogenesis is vessel maturation evidenced by the
recruitment of pericytes [42,43]. Endothelial and/or pericyte fibro-
nectin could promote maturation by supporting tube stabilization
[30,44] and recruitment of mesenchymal cells to sites of vascular
remodeling [34]. In line with these data, our findings suggest that
fibronectin modulates recruitment and differentiation of pericytes.
Fibronectin isoforms EDA and EDB [18,19] are expressed in newly
formed blood vessels in tumors [45–47]. Even though the absence of
either one did not affect tumor neovascularization [45], the simulta-
neous absence of both was associated with defects in early vessel for-
mation and diminished maturation in transgenic mice [48]. These
findings are extended by our results showing a more pronounced
decrease in vessel maturation in Mx-cKO compared to Alb-cKO
tumors and attributing this effect to loss of endothelial and pericyte
fibronectin production. The decrease in vessel maturation in Alb-
cKO tumors however additionally implicates circulating fibronectin
in pericyte recruitment, possibly because of the ability of circulating
fibronectin to increase its production locally through a positive feed-
back loop as shown. The effects of circulating fibronectin may thus
partially explain the incomplete effects seen with use of angiogenesis
inhibitors [49].
Table 2. Clinical and Histopathologic Characteristics of the Patients in the Second Prostate Tissue Microarray.
Effect Level Number of Patients Cancer-Specific Survival Time to Local Recurrence Time to Metastasis Formation
Global P Events HR with 95% CI Global P Events HR with 95% CI Global P Events HR with 95% CI
PSA (ng/ml) ≤4 18 .168 0 (Ref.) .196 3 (Ref.) .335 1 (Ref.)
4-10 33 2 2 × 105 (0 to >1010) 11 2.70 (0.75-9.75 4 2.74 (0.30-24.73)
>10 38 4 664 (0 to >1010) 13 1.56 (0.67-3.61) 6 1.81 (0.47-7.04)
89
T 0 54 .053 2 (Ref.) <.001 11 (Ref.) .001 3 (Ref.)
1 29 4 4.65 (0.84-25.6) 16 4.66 (2.10-10.35) 8 6.88 (1.81-26.14)
N 0 83 .001 4 (Ref.) <.001 24 (Ref.) .002 9 (Ref.)
1 5 2 9.86 (1.79-54.45) 3 6.74 (1.98-22.90) 2 8.03 (1.70-37.96)
Gleason score 0-7a 70 .004 2 (Ref.) .004 17 (Ref.) .003 5 (Ref.)
>7a 19 4 8.02 (1.47-43.84) 10 2.96 (1.36-6.48) 6 5.09 (1.55-16.67)
Resection R0 71 .007 3 (Ref.) .001 18 (Ref.) .015 7 (Ref.)
R1 18 3 7.27 (1.36-38.78) 9 3.68 (1.64-8.26) 4 4.29 (1.21-15.23)
Fibronectin score 0 41 .031 3 (Ref.) .086 11 (Ref.) .004 4 (Ref.)
1 36 0 – 13 1.98 (0.85-4.63) 4 2.48 (0.56-10.99)
2 12 3 3390 (0 to >1010) 3 1.63 (0.49-5.47) 3 6.71 (1.72-26.08)
Fibronectin score 0 + 1 77 <.001 3 (Ref.) .420 24 (Ref.) .001 8 (Ref.)
2 12 3 12.83 (2.46-66.92) 3 1.64 (0.49-5.49) 3 7.00 (1.77-27.64)
PSA indicates prostate-specific antigen; T, tumor size; N, nodal status; HR, hazard ratio; CI, confidence interval; Ref., reference. Significant P values are bolded.
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The correlation between the amount of fibronectin in the tumor
and both blood vessels and cancer growth is a central result of our
study. Our data demonstrate that the amount of fibronectin within
the tumor controls VEGF content and modulates VEGF-mediated
signaling and, hence, blood vessel formation and subsequent tumor
growth. Since it might be difficult to quantify fibronectin in samples
received by pathologists, we examined whether fibronectin staining
provides useful information about tumor growth based on sugges-
tions in a prior study [50]. Indeed, staining intensity correlated with
tumor growth in our model and with death in patients with breast
and prostate cancers. In prostate cancer, death was best predicted by
fibronectin staining intensity, which could be used to identify patients
who require more aggressive therapy.
In summary, we show that circulating fibronectin plays a critical
role in tumor growth. Circulating, cancer cell and endothelial/pericyte
fibronectin cooperate to induce blood vessel formation and matura-
tion and, hence, tumor growth by modifying VEGF content in tumors
and potentiating VEGF-mediated signaling and effects. As a conse-
quence, tumor fibronectin correlates with tumor growth in mice and
is predictive of death in patients with breast and prostate cancers. This
work thus expands on the traditional cell- and microenvironment-
centered view of cancer growth and opens up new perspectives on
the understanding of cancer growth.
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Figure W1. (A)Western blot of bonemarrow lysate confirms decreased fibronectin content (FN) inMx-cKO and normal content in Alb-cKO.
Bone marrow was flushed with 100 μl of protein lysis buffer/femur. (B) Bioluminescence signal after intracardiac injection of MDA-
MB-231/B+: 1 hour after intracardiac injection, a very weak signal can be detected (embedded A), which is gone by 24 hours after
injection (embedded B). Lesions are detected by 3 weeks after injection (embedded C). To measure the bioluminescence signal, mice were
injected with 150mg/kg luciferin exactly 5 minutes before starting measurements. (C) Intracardiac injection of MDA-MB-231 in Alb- and
Mx-cKO mice results in a similar number of lesions per mouse as determined by BLI. The x-axis represents weeks since intracardiac
injection (N = 11-12/group). (D) Homing of cancer cells to the bone marrow was not affected by the deletion of circulating fibronectin
and/or fibronectin in the bone marrow, as determined by qPCR. Cancer cells (105) were injected intracardially, and 24 hours later, DNA
was extracted and examined by qPCR for human alu. Results are adjusted to murine bone marrow (N = 6/group). (E) Intratibial injection
is associated with a decrease in growth in both Alb- and Mx-cKO. The results of bioluminescence signal measurements are shown in
Figure 1F . The decrease in thearea of osteolysis at theendof theexperiment at day 40 after intratibial injection is shownhere (N =9-11/group).
*P < .05.
Figure W2. Findings in a model of prostate cancer. Tumor cells of the line PC3Mpro4/luc+ were injected intratibially in male mice, and
bioluminescence signal was examined at the time points shown on A. (A) Decreased growth by bioluminescence signal (N = 12/group).
(B) Area of osteolysis was diminished at the time of death 40 days after intratibial injection.
Figure W3. Confirmation of identity of isolated endothelial cells and pericytes. (A) Endothelial cells isolated using CD31-coated Dyna-
beads stained positive for both vWF and CD31. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). Cancer cells did not show
any staining with either endothelial cell markers. Bars represent 50 μm. (B) Pericytes isolated by sorting stained positive for both
angiopoietin-1 and α-SMA by flow cytometry.
Figure W4. Angiogenesis in a prostate cancer model. Tumor cells of the line PC3Mpro4/luc+ were injected intratibially in male mice.
Forty days after injection, mice were killed and tumors were examined using CD31 staining. There was a significant decrease in blood
vessel numbers in Alb-cKO and Mx-cKO tumors, but no difference between Alb- and Mx-cKO tumors (N = 4/group). *P < .05.
Figure W5. Effects of fibronectin on vessel maturation. (A) CD31+ blood vessels were additionally stained with α-SMA. Bars represent
200 μm. (B) A detailed view of a blood vessel co-stained with CD31 and α-SMA. The quantification is shown in Figure 3E and in C.
(C) CD31+ blood vessel number was decreased in both cKO models to almost the same degree compared to CT (total). In addition,
there was a decrease in double positive CD31+ α-SMA+ blood vessels in both cKOs, but their percentage was higher in Alb-cKO com-
pared to Mx-cKO. The number of blood vessels corrected to the area in CT tumors was set at 100% to allow for comparison of relative
changes between the groups. #P < .05 for α-SMA+ versus total in each group (N = 3, 3, 6 mice, four sections/mouse). (D) This graph is
similar to C except that it shows the data for desmin staining instead of α-SMA. The number of blood vessels corrected to the area in CT
tumors was set at 100% to allow for comparison of relative changes between the groups. #P < .05 for desmin+ versus total in each
group. N as in C. (E) The decrease in the percentage of desmin+ blood vessels was more pronounced in Mx- than in Alb-cKO tumors.
For the purpose of this graph, CT, Alb-cKO, and Mx-cKO CD31+ vessels were set at 100%. This graph is similar to Figure 3E except that
it shows the data for desmin staining instead of α-SMA. N as in C. (F) Relative mRNA expression of the pericyte marker RGS5 was
diminished in both cKOs (N = 7 CT, 4 Alb-cKO, and 5 Mx-cKO). *P < .05, **P < .01.
Figure W6. Changes in VEGF, VEGFR-2, and signaling in vivo and in vitro. (A) Murine VEGF originating from stromal cells was not
affected in cKO tumors (measured using murine-specific ELISA), while cancer cell (human) VEGF was (shown in Figure 4A; N = 4-6/group).
(B) Neither cancer cell nor stromal VEGF mRNA differed between CT and cKO tumors (N = 4/group). (C) Cancer cell (human) VEGFR-2
mRNA expression was not affected in cKO tumors, but murine VEGFR-2 (shown in Figure 4D) was (N = 4/group). (D) Cell proliferation
was significantly increased when endothelial cells were treated with either fibronectin or VEGF compared to untreated cells, except for
Mx-cKO endothelial cells, which failed to proliferate in response to VEGF alone. The addition of both simultaneously resulted in a more
pronounced increase in proliferation in the three groups; # denotes significant change compared to baseline proliferation; § denotes
significant increase compared to either fibronectin (FN) or VEGF alone (N = 3 experiments with three to five replicates/condition per
experiment. (E and F) Fibronectin, VEGF, or the combination of both does not affect FAK (E) or JNK (F) phosphorylation in tumor endothelial
cells. The data are the average of four experiments with three to five replicates/condition per experiment. Equal amounts of protein as
measured by BCA were loaded. The Western blot is shown in Figure 4G .
Figure W7. Effects of fibronectin on apoptosis. (A) Apoptosis in tumor was determined by digesting tumor tissue followed by staining for
AV and PI. (B) The number of tumor cells stained positive with AV (AV+/PI+ and AV+/PI−) is increased in Mx-cKO and Alb-cKO tumors
(N = 3/group). (C) Cleaved caspase-3 was not affected in Mx- and Alb-cKO tumors compared to CT. Bars represent 100 μm. (D) Quanti-
fication confirms absence of a difference (N = 6 CT, 3 Alb-cKO, and 3 Mx-cKO).
Figure W8. Correlations between fibronectin staining in intratibial MDA-MB-231b/luc+ tumors and blood vessel numbers or biolumines-
cence signal. (A) Area of fibronectin staining correlates with blood vessel numbers (N = 4 CT, 3 Alb-cKO, and 3 Mx-cKO). (B) Area of
fibronectin staining correlates with bioluminescence signal in the same groups as A.
